Chemotherapy (AACR Conference News)

Study: Taxol Derivative Is Less Toxic, More Effective

Published in Cancer Weekly, April 26th, 1999

Scientists from the M.D. Anderson Cancer Center reported that PG-TXL, a potentially less toxic and more effective derivative of the world's most widely used cancer drug Taxol, dramatically increases the sensitivity of tumor cells to the killing effects of radiation.

Preclinical findings suggest PG-TXL may be used effectively in combination with radiation therapy to expand its potential application to a broader population of cancer patients.

According to the American College of Radiology, 50 percent of all cancer patients receive radiation therapy during the course of their disease. Despite its use, radiation fails to cure cancer in the majority...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (1999-04-26)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry